Sequoia Pharmaceuticals Secures Funding to Test its Unique AIDS Drug

Sequoia Pharmaceuticals, Inc., a company focused on discovering novel drugs to combat drug-resistant viral infections, announced that it closed on a $22 million Series B round of financing. The financing is expected to fund early stage clinical trials of the company's novel drug designed to combat wild-type- and multi-drug-resistant strains of HIV.

PR Web (http://www.prweb.com/releases/2005/3/prweb219954.php)